Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex (NYSE: TFX) declared a quarterly cash dividend of $0.34 per share. The dividend is payable on December 15, 2025 to shareholders of record at the close of business on November 14, 2025.
This announcement sets the payment and record dates for the next quarterly distribution to common shareholders.
Teleflex (NYSE: TFX) reported third-quarter 2025 results: GAAP revenue $913.0M (+19.4% YoY) and adjusted revenue $892.9M (+16.8% YoY). GAAP diluted EPS from continuing operations was $(9.24) versus $2.36 prior year; adjusted diluted EPS was $3.67 versus $3.49 prior year. The company narrowed full-year 2025 GAAP revenue growth guidance to 9.10%–9.60%, lowered adjusted constant currency revenue growth to 6.90%–7.40%, cut GAAP EPS guidance to $(4.42)–$(4.22) and narrowed adjusted EPS to $14.00–$14.20.
Notable items: $403.9M goodwill impairment (Interventional Urology), $100M Titan SGS impairment, total impairments ~$512.0M, cash $381.3M, inventories $802.5M, and a Vascular Intervention integration plan with $36–44M restructuring costs and expected annual savings of $24–30M.
Teleflex (NYSE:TFX) will hold its Q3 2025 earnings conference call on Thursday, November 6, 2025 at 8:00 a.m. ET to discuss third-quarter results and provide an operational update. Participants should pre-register to receive dial-in information; a live audio webcast will be available at teleflex.com. An audio replay begins at 11:00 a.m. ET on November 6, 2025 and is accessible via the website or by phone at 1 800 770 2030 (U.S./Canada) or 1 609 800 9909 (international) using conference ID 69028.
Teleflex will also host a Vascular Intervention virtual investor meeting on November 14, 2025 at 8:00 a.m. ET to review its recent Vascular Intervention acquisition and product portfolio; pre-registration and a live webcast are available at teleflex.com.
Teleflex (NYSE:TFX) has initiated the DUBSTENT DIABETES trial with the enrollment of its first patient. This randomized, investigator-initiated clinical study aims to evaluate a dual-device strategy for percutaneous coronary intervention (PCI) in diabetic patients.
The trial will compare three approaches: a combination of Pantera Lux DCB Catheter with Orsiro Mission DES, Pantera Lux DCB alone, and Orsiro Mission DES alone. The study will enroll 120 diabetes patients across Irish centers, with primary endpoints measuring diameter stenosis at six months and secondary endpoints tracking various cardiac events over five years.
Teleflex (NYSE:TFX) announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The presentation is scheduled for Tuesday, September 9, 2025, at 3:20 p.m. ET at the Sheraton New York Times Square. Investors can access the live audio webcast through the company's investor relations website at teleflex.com.
Teleflex (NYSE:TFX) has launched its Barrigel™ rectal spacer in Japan following regulatory approval from the Japanese PMDA. The product is a non-animal stabilized hyaluronic acid spacer designed to reduce rectal radiation exposure during prostate cancer radiation therapy.
Clinical data shows 98% of patients achieved at least a 25% reduction in radiation to the rectum, with average reductions of 85% in rectal V54 Gy radiation. The launch is particularly significant as prostate cancer was Japan's most common cancer among men in 2022, with 104,318 new cases, representing 18% of all cancer diagnoses in the country.
Initial cases have already commenced in Japan under the direction of Dr. Jun Itami, with the product now available for immediate purchase following insurance coverage acceptance.
Teleflex (NYSE:TFX) has announced its latest quarterly dividend. The company's Board of Directors has declared a cash dividend of $0.34 per share of common stock. The dividend will be paid on September 15, 2025, to shareholders who are on record as of August 15, 2025.
Teleflex (NYSE:TFX) reported strong Q2 2025 financial results, with GAAP revenue reaching $780.9 million, up 4.2% year-over-year, and adjusted constant currency growth of 1.0%. The company achieved GAAP diluted EPS from continuing operations of $2.77 and adjusted diluted EPS of $3.73.
Following the successful acquisition of BIOTRONIK's Vascular Intervention business, Teleflex raised its 2025 guidance, now expecting GAAP revenue growth of 9.00% to 10.00% and adjusted constant currency revenue growth of 7.70% to 8.70%. The company also increased its adjusted diluted EPS guidance to $13.90-$14.30.
By segment, Americas revenue grew 1.9%, EMEA increased 13.0%, and Asia rose 2.3% in Q2. The Interventional category showed the strongest performance with 20.4% growth, while OEM and Interventional Urology experienced declines of 11.4% and 8.1% respectively.
Teleflex (NYSE:TFX) has scheduled its second quarter 2025 earnings conference call for Thursday, July 31, 2025, at 8:00 a.m. Eastern Time. The company will discuss financial results and provide an operational update during the call.
Investors can access the call through pre-registration or via a live audio webcast on teleflex.com. An audio replay will be available from 11:00 am ET on the same day, accessible through the company website or by phone using the conference ID 69028.
Teleflex (NYSE:TFX) has completed its acquisition of BIOTRONIK's Vascular Intervention business for €760 million in cash. The acquisition significantly enhances Teleflex's global presence in the catheterization laboratory and establishes its footprint in the growing peripheral intervention market.
The acquired portfolio includes key products for coronary and peripheral interventions such as the Pantera Lux Drug-Coated Balloon Catheter, PK Papyrus Covered Coronary Stent, and Orsiro Mission Drug Eluting Stent. The deal also includes Freesolve, a CE-marked sirolimus-eluting Resorbable Metallic Scaffold technology.
Financially, the acquired products are expected to generate €177 million ($204 million) in revenues for the second half of 2025, with €91 million ($105 million) projected for Q4 2025. From 2026, the business is anticipated to deliver annual constant currency revenue growth of 6% or better. The transaction is expected to be $0.10 accretive to Teleflex's adjusted earnings per share in the first year.